495 related articles for article (PubMed ID: 19000363)
1. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
Gordon S; Saupe A; McBurney W; Rades T; Hook S
J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery.
Gordon S; Teichmann E; Young K; Finnie K; Rades T; Hook S
Eur J Pharm Sci; 2010 Oct; 41(2):360-8. PubMed ID: 20633644
[TBL] [Abstract][Full Text] [Related]
3. Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.
Gordon S; Young K; Wilson R; Rizwan S; Kemp R; Rades T; Hook S
J Liposome Res; 2012 Sep; 22(3):193-204. PubMed ID: 22188610
[TBL] [Abstract][Full Text] [Related]
4. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
5. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
Sexton A; Whitney PG; Chong SF; Zelikin AN; Johnston AP; De Rose R; Brooks AG; Caruso F; Kent SJ
ACS Nano; 2009 Nov; 3(11):3391-400. PubMed ID: 19824668
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
7. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
Amidi M; Romeijn SG; Borchard G; Junginger HE; Hennink WE; Jiskoot W
J Control Release; 2006 Mar; 111(1-2):107-16. PubMed ID: 16380189
[TBL] [Abstract][Full Text] [Related]
9. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
[TBL] [Abstract][Full Text] [Related]
10. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
11. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
12. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy.
Pandey RS; Sahu S; Sudheesh MS; Madan J; Kumar M; Dixit VK
Int Immunopharmacol; 2011 Aug; 11(8):925-31. PubMed ID: 21333772
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
Slütter B; Soema PC; Ding Z; Verheul R; Hennink W; Jiskoot W
J Control Release; 2010 Apr; 143(2):207-14. PubMed ID: 20074597
[TBL] [Abstract][Full Text] [Related]
14. Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems.
Kojarunchitt T; Baldursdottir S; Dong YD; Boyd BJ; Rades T; Hook S
Eur J Pharm Biopharm; 2015 Jan; 89():74-81. PubMed ID: 25481034
[TBL] [Abstract][Full Text] [Related]
15. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
[TBL] [Abstract][Full Text] [Related]
16. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
[TBL] [Abstract][Full Text] [Related]
17. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
Jiang L; Qian F; He X; Wang F; Ren D; He Y; Li K; Sun S; Yin C
J Gene Med; 2007 Apr; 9(4):253-64. PubMed ID: 17397104
[TBL] [Abstract][Full Text] [Related]
18. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
19. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
Mahmoud AA; El-Feky GS; Kamel R; Awad GE
Int J Pharm; 2011 Jul; 413(1-2):229-36. PubMed ID: 21540097
[TBL] [Abstract][Full Text] [Related]
20. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
Bilensoy E; Sarisozen C; Esendağli G; Doğan AL; Aktaş Y; Sen M; Mungan NA
Int J Pharm; 2009 Apr; 371(1-2):170-6. PubMed ID: 19135514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
